A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

TRANSFORM: A 24-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 2B TRIAL OF SETANAXIB IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND ELEVATED LIVER STIFFNESS

Intervention/treatment:
SETANAXIB (GKT137831)
Medical condition:
PRIMARY BILIARY CHOLANGITIS (PBC)
Protocol code:
GSN000350
Control number:
257383
Status:
Closed
Approved:
November 05, 2021
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05014672
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Head of Clinical Operations
Organization
Calliditas Therapeutics AB
Phone:
+4684113005
Sponsor
CALLIDITAS THERAPEUTICS AB

Locations

Alberta

University of Calgary
Calgary, Alberta, T2N 4Z6

Nova Scotia

Queen Elizabeth II Health Sciences Centre - Victoria General
Halifax, Nova Scotia, B3H 3A7

Ontario

Centricity Research (LMC Manna Research) - London
London, Ontario, N6A 2C2
Office Of Stephane M. Gauthier
North Bay, Ontario, P1B 2H3
St. Joseph's Healthcare Hamilton - Charlton Campus
Hamilton, Ontario, L8N 4A6
Toronto Liver Center
Toronto, Ontario, M6H 3M1
William Osler Health System - Brampton Civic Hospital
Brampton, Ontario, L6R 3J7

Quebec

Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 3J4

Results

See the results from the trial NCT05014672. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?